Black Diamond Therapeutics, Inc. BDTX
1.66 USD +0.07 (+4.33%)
Nov 11, 2026, 9:31 AM EST
1.66 Day range 1.69
1.58 52-week range 4.94
- YTD
- -31.52%
- 1 year
- -61.83%
News
benzinga.com Why Is Black Diamond Therapeutics Stock Soaring Tuesday? Black Diamond Therapeutics Inc. (NASDAQ:BDTX) on Tuesday reported updated Phase 2 data for its targeted cancer candidate silevertinib, detailing regulatory next steps following a pivotal U.S. Food…
benzinga.com Why Is Black Diamond Therapeutics Stock Soaring Tuesday? Black Diamond Therapeutics reports Phase 2 silevertinib data, outlines FDA Phase 3 plans, and confirms cash runway extending into late 2028.
seekingalpha.com Black Diamond Therapeutics, Inc. (BDTX) Discusses Silevertinib Phase II Data and Phase III Development Plans Transcript Black Diamond Therapeutics, Inc. (BDTX) Discusses Silevertinib Phase II Data and Phase III Development Plans Transcript
benzinga.com Black Diamond Therapeutics Reports Updated Phase 2 Silevertinib Data, FDA End-Of-Phase 2 Feedback, Supporting Pivotal Development In All 1L EGFR-NCM NSCLC Patients With Potential For Accelerated Approval Based On CNS-ORR Updated Phase 2 results demonstrate robust CNS activity, including 86% CNS-ORR and mPFS double that of currently available EGFR TKIs, in patients with untreated brain metastasesRecent End-of-Phase 2…
globenewswire.com Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic…
benzinga.com Black Diamond Therapeutics To Host A Webcast For Investors To Present Updated Results From Its Ongoing Phase 2 Trial Of Silevertinib Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including…
benzinga.com HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11 price target.
benzinga.com Black Diamond Therapeutic Q2 EPS $(0.17) Beats $(0.19) Estimate Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 10.53 percent increase over…
benzinga.com What's Going On With Black Diamond Therapeutics Stock Tuesday? Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com Black Diamond Therapeutics' Silevertinib Shows 15.2-Month Median PFS And 60% Response Rate With CNS Activity In EGFR Non-Classical Mutation NSCLC Phase 2 Study Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in patients with a broad spectrum of EGFR-NCMs, including…
benzinga.com BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11 BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.
benzinga.com Black Diamond To Present Phase 2 Data Of Silevertinib In Recurrent EGFRm NSCLC Patients And Trial-In-Progress Poster On Randomized Phase 2 Trial Of Silevertinib In EGFRvIII-Positive GBM At 2026 ASCO Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patientsTrial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients…- benzinga.com Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14 Wedbush analyst Robert Driscoll maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and raises the price target from $13 to $14.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com US Stocks Mixed; Dollar Tree Posts Upbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals 4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Nanobiotix, NanoString Technologies And Other Big Stocks Moving Higher In Monday's Pre-Market Session U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
- benzinga.com Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket Gainers Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 123% to $3.48 in pre-market trading after dropping over 8% on Wednesday.
benzinga.com Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market.- benzinga.com Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
- benzinga.com Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force.
benzinga.com $3 Million Bet On Taysha Gene Therapies? Check Out These 3 Penny Stocks Insiders Are Buying The Dow Jones closed lower by more than 500 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or…- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 101 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 528 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 215 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 540 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 149 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 435 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 211 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.- benzinga.com 53 Biggest Movers From Yesterday Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 64.4% to close at $1.41 on Thursday. Ally Bridge Group reported a purchase of 21.176 million shares of MedAvail Holdings for an average…
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2022 Upgrades
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 107 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 348 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 445 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's morning session, 216 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Monday morning saw 115 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows.